Stock Ratings / Health Care / COCH / forecast

MYO (37) APT (58) NTRB (40) CNXU (56) ⌘ Pro Terminal →

Envoy Medical Inc. (Class A) (COCH) 12-Month Stock Forecast & Price Target Cone

$6.50 -2.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.46

Envoy Medical Inc. (Class A) (COCH) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $50.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.46 (-0.62%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COCH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY COCH SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (31% of score)

FRED Regime × Technicals: 49% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$6.58+1.5% Next Q

Q2 (-2Q)

Grade D$6.68-10.8% Next Q

Q3 (-1Q)

Grade D$5.96+9.1% Next Q

Current

Grade D-$6.50-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a COCH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While COCH currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.86) and Max Pain ($6.83) forces dealer call-delta covering toward $10.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $COCH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “COCH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your COCH Position Size: $10,000

Shares at $6.50: 1538.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.70

$7,231

$-2,769 (-27.7%)

12M Consensus BaseTarget $6.03

$9,277

$-723 (-7.2%)

12M Bull Case BreakoutTarget $10.02

$15,415

+$5,415 (+54.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$9	69%	B
JP MorganUS Large-Cap Research	SELL	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COCH)

✓Walkthrough of COCH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

COCH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.41%▼ DESCENDING CHANNEL

2026-10-30O $6.28H $6.70L $6.26C $6.50VOL 48.4K

RES: $7.01SUP: $4.67SMA50: $6.86SMA200: $6.87

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

COCH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 COCH Butterfly Map → + Track COCH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +7.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on COCH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for COCH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for COCH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COCH)

Health Care Rank #584 of 1016 ⚔️ MYO vs COCH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (COCH vs. MYO, APT, NTRB, CNXU)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Envoy Medical Inc. (Class A) (COCH) ranks #584 by composite RQD confidence (42/100, grade D-) and #752 by equity capitalization ($50.3M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with COCH at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
COCH ACTIVE Envoy Medical Inc. (Class A)	D-	42/100	—	-30.0%	-35.0%	-2.40%	$50.3M	Benchmark Subject
MYO Myomo Inc.	D-	37/100	—	65.7%	-35.0%	+3.18%	$51.5M	/myo-vs-coch →
APT Alpha Pro Tech Ltd.	D+	58/100	16.2x	38.1%	6.7%	+1.28%	$56.6M	/apt-vs-coch →
NTRB Nutriband Inc.	D-	40/100	—	27.8%	-35.0%	+3.75%	$80.7M	/ntrb-vs-coch →
CNXU Conexeu Sciences Inc.	D+	56/100	—	—	—	-1.74%	$85.8M	/cnxu-vs-coch →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840877

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Envoy Medical Inc. (Class A) (COCH) reported GAAP revenue of $241.0K (+7.1% vs. FY2024 revenue of $225.0K , and -23.7% cumulative change since FY2023) , GAAP net income of -$23.8M, operating cash flow of -$18.2M, and free cash flow of -$18.4M (+2.9% YoY). On the balance sheet, COCH closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$241.0K	-$23.8M	-$18.2M	-$18.4M	$8.6M	—
FY2024 (FY)	2024-12-31	$225.0K	-$20.8M	-$17.9M	-$18.9M	$11.5M	—
FY2023 (FY)	2023-12-31	$316.0K	-$29.9M	-$17.1M	-$17.1M	—	—

3. COCH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is COCH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Envoy Medical Inc. (Class A) (NASDAQ: COCH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $6.50 (-2.40% 1D, market cap $50.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, COCH ranks #584 in composite RQD confidence.

How does COCH compare to MYO and APT in the Health Care sector?

Within the Health Care sector (Industrial Specialties), COCH carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MYO (Myomo Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M) and APT (Alpha Pro Tech Ltd.) posts a D+ grade (58/100 RQD, P/E 16.2x, ROIC 6.7%, cap $56.6M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for COCH?

Per COCH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840877), Envoy Medical Inc. (Class A) generated $241.0K in revenue (+7.1% YoY), -$23.8M in net income, and -$18.4M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is COCH trading relative to its 50-day, 200-day, and 52-week technical levels?

COCH last traded at $6.50 (-2.40% on volume of 96,593 shares), positioning the stock -5.25% below its 50-day simple moving average ($6.86) and -5.39% below its 200-day simple moving average ($6.87). Across its 52-week range of $3.63 to $9.54, COCH sits at the 48.6% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.69 to $7.31).

COCH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is COCH's 12-month stock price target?

Envoy Medical Inc. (Class A) (COCH) carries a 12-month consensus base price target of $6.03 (-7.2% from $6.50), with a bull-case target of $10.02 and a bear-case floor of $4.7.

Is COCH stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates COCH D- (Sell — SELL) with an RQD Confidence score of 42/100.

Direct Sub-Reports: COCH RQD Cockpit COCH 12M Forecast COCH Earnings & Move COCH Dividends & DRIP COCH Insiders & 13F COCH Whale Options COCH Profit Sankey COCH News & Why